© Vésale/BioFit

Phage therapy specialist Vésale Bioscience gas bageds €1.8m  from European Innovation Council (EIC) to fight antibiotic resistance (AMR).

The Great Pacific Garbage Patch, Picture: © bennymarty - stock.adobe.com

A decade ago, the news about the Great Pacific Garbage Patch went viral. Since then, a multitude of startups proliferated on a mission to create ecological alternatives to the ubiquitous fossil-based plastics. At ECBF, we are closely monitoring the emerging materials for packaging applications, by far the main use case of plastics.

© Abionyx Pharma

Abionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001,  a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI)
 

© BioNTech SE

BioNTech SE will pay £562m in cash to acquire its former partner InstaDeep Ltd. to expand its capabilities in AI-based drug discovery.

Stucture of the AI Health Innovation Cluster in Heidelberg, Germany

The AI Health Innovation Cluster is bringing together leading scientists at the ­interface
of artificial intelligence (AI), healthcare, and data science. The goal is to combine and further develop the outstanding research networks and infrastructures in modern health data sciences that have emerged in the Rhine-Neckar region in Germany in recent years.

PD-L1 blocks PD-L1 and B7.1 receptors on T cells thus triggering inactivation of cytotoxic T cells. © Genbentech Inc

Roche AG’s US subsidiary Genentech Inc has withdrawn its checkpoint inhibitor atezolizumab from the market after disappointing results in bladder cancer.

Biotech manufacturing plant at CZ Vaccines, Spain; © CZ Vaccines

SARS-COV-2 exposed our vulnerability and strategic weakness at European­ level, in terms of biotechnological manufacturing capacity.

© geralt/pixabay.com

Evosep APS has inked a $40m funding deal with Novo Holdings A/S that is aimed to advance standardised clinical LC-MS-based drug discovery and diagnostic multi-marker tests.

Exevir BIO executive team at EIB. © EIB/Exevir BIO

With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.

© Synaffix BV

Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.